Medical - Diagnostics & Research
Compare Stocks
4 / 10Stock Comparison
SERA vs INVA vs NTRA vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Diagnostics & Research
Drug Manufacturers - Specialty & Generic
SERA vs INVA vs NTRA vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Biotechnology | Medical - Diagnostics & Research | Drug Manufacturers - Specialty & Generic |
| Market Cap | $73M | $1.93B | $31.16B | $1.61B |
| Revenue (TTM) | $57K | $424M | $2.31B | $4.18B |
| Net Income (TTM) | $-32M | $504M | $-208M | $-1.82B |
| Gross Margin | -191.2% | 76.2% | 64.8% | 34.2% |
| Operating Margin | -642.4% | 14.8% | -13.4% | -4.1% |
| Forward P/E | — | 11.9x | — | 5.6x |
| Total Debt | $2M | $269M | $214M | $3.97B |
| Cash & Equiv. | $4M | $551M | $1.08B | $532M |
SERA vs INVA vs NTRA vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Sera Prognostics, I… (SERA) | 100 | 17.1 | -82.9% |
| Innoviva, Inc. (INVA) | 100 | 160.8 | +60.8% |
| Natera, Inc. (NTRA) | 100 | 191.9 | +91.9% |
| Perrigo Company plc (PRGO) | 100 | 24.4 | -75.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SERA vs INVA vs NTRA vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SERA lags the leaders in this set but could rank higher in a more targeted comparison.
INVA carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
- Beta 0.13, current ratio 14.64x
- 118.9% margin vs SERA's -563.9%
- Beta 0.13 vs SERA's 1.56
NTRA is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 35.9%, EPS growth 0.7%, 3Y rev CAGR 41.1%
- 20.9% 10Y total return vs INVA's 94.9%
- 35.9% revenue growth vs PRGO's -2.8%
- +37.3% vs PRGO's -51.2%
PRGO is the clearest fit if your priority is income & stability.
- Dividend streak 10 yrs, beta 1.18, yield 9.8%
- Better valuation composite
- 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 35.9% revenue growth vs PRGO's -2.8% | |
| Value | Better valuation composite | |
| Quality / Margins | 118.9% margin vs SERA's -563.9% | |
| Stability / Safety | Beta 0.13 vs SERA's 1.56 | |
| Dividends | 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +37.3% vs PRGO's -51.2% | |
| Efficiency (ROA) | 32.4% ROA vs SERA's -30.9%, ROIC 14.2% vs -46.2% |
SERA vs INVA vs NTRA vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SERA vs INVA vs NTRA vs PRGO — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
INVA leads in 3 of 6 categories
PRGO leads 2 • NTRA leads 1 • SERA leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
INVA leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 73305.3x SERA's $57,000. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to SERA's -563.9%. On growth, NTRA holds the edge at +39.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $57,000 | $424M | $2.3B | $4.2B |
| EBITDAEarnings before interest/tax | -$36M | $86M | -$310M | $58M |
| Net IncomeAfter-tax profit | -$32M | $504M | -$208M | -$1.8B |
| Free Cash FlowCash after capex | -$28M | $181M | $97M | $108M |
| Gross MarginGross profit ÷ Revenue | -191.2% | +76.2% | +64.8% | +34.2% |
| Operating MarginEBIT ÷ Revenue | -642.4% | +14.8% | -13.4% | -4.1% |
| Net MarginNet income ÷ Revenue | -563.9% | +118.9% | -9.0% | -43.5% |
| FCF MarginFCF ÷ Revenue | -483.8% | +42.8% | +4.2% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -63.2% | +10.6% | +39.8% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +15.0% | +4.0% | +185.4% | -56.4% |
Valuation Metrics
PRGO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than INVA's 8.1x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $73M | $1.9B | $31.2B | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $72M | $1.7B | $30.3B | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -2.87x | 6.91x | -144.62x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 11.91x | — | 5.56x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.67x | — | — |
| EV / EBITDAEnterprise value multiple | — | 8.10x | — | 7.42x |
| Price / SalesMarket cap ÷ Revenue | 905.27x | 4.55x | 13.51x | 0.38x |
| Price / BookPrice ÷ Book value/share | 1.21x | 1.65x | 17.55x | 0.55x |
| Price / FCFMarket cap ÷ FCF | — | 9.88x | 285.53x | 11.12x |
Profitability & Efficiency
INVA leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-51 for PRGO. SERA carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), INVA scores 5/9 vs SERA's 2/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -41.0% | +46.5% | -15.3% | -50.7% |
| ROA (TTM)Return on assets | -30.9% | +32.4% | -10.6% | -19.8% |
| ROICReturn on invested capital | -46.2% | +14.2% | -36.1% | +3.7% |
| ROCEReturn on capital employed | -58.2% | +12.4% | -18.3% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.03x | 0.23x | 0.13x | 1.35x |
| Net DebtTotal debt minus cash | -$2M | -$282M | -$862M | $3.4B |
| Cash & Equiv.Liquid assets | $4M | $551M | $1.1B | $532M |
| Total DebtShort + long-term debt | $2M | $269M | $214M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | -12560.33x | 63.45x | -25.21x | -7.20x |
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NTRA five years ago would be worth $21,587 today (with dividends reinvested), compared to $1,613 for SERA. Over the past 12 months, NTRA leads with a +37.3% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors NTRA at 60.6% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -36.0% | +14.7% | -3.9% | -13.5% |
| 1-Year ReturnPast 12 months | -20.0% | +21.7% | +37.3% | -51.2% |
| 3-Year ReturnCumulative with dividends | -45.1% | +95.2% | +314.0% | -58.1% |
| 5-Year ReturnCumulative with dividends | -83.9% | +94.4% | +115.9% | -60.1% |
| 10-Year ReturnCumulative with dividends | -83.9% | +94.9% | +2089.4% | -77.7% |
| CAGR (3Y)Annualised 3-year return | -18.1% | +25.0% | +60.6% | -25.2% |
Risk & Volatility
INVA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
INVA is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than SERA's 1.56 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INVA currently trades 90.7% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.56x | 0.13x | 1.26x | 1.18x |
| 52-Week HighHighest price in past year | $4.09 | $25.15 | $256.36 | $28.44 |
| 52-Week LowLowest price in past year | $1.37 | $16.52 | $131.81 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +46.9% | +90.7% | +85.7% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 41.4 | 39.9 | 57.1 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 55K | 621K | 1.3M | 3.4M |
Analyst Outlook
PRGO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: SERA as "Buy", INVA as "Buy", NTRA as "Buy", PRGO as "Hold". Consensus price targets imply 160.4% upside for SERA (target: $5) vs 19.4% for NTRA (target: $263). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $5.00 | $37.67 | $262.50 | $20.00 |
| # AnalystsCovering analysts | 5 | 10 | 27 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +9.8% |
| Dividend StreakConsecutive years of raises | — | 0 | — | 10 |
| Dividend / ShareAnnual DPS | — | — | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.2% | 0.0% | 0.0% |
INVA leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 2 (Valuation Metrics, Analyst Outlook).
SERA vs INVA vs NTRA vs PRGO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SERA or INVA or NTRA or PRGO a better buy right now?
For growth investors, Natera, Inc.
(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Sera Prognostics, Inc. (SERA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SERA or INVA or NTRA or PRGO?
On forward P/E, Perrigo Company plc is actually cheaper at 5.
6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — SERA or INVA or NTRA or PRGO?
Over the past 5 years, Natera, Inc.
(NTRA) delivered a total return of +115. 9%, compared to -83. 9% for Sera Prognostics, Inc. (SERA). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus SERA's -83. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SERA or INVA or NTRA or PRGO?
By beta (market sensitivity over 5 years), Innoviva, Inc.
(INVA) is the lower-risk stock at 0. 13β versus Sera Prognostics, Inc. 's 1. 56β — meaning SERA is approximately 1137% more volatile than INVA relative to the S&P 500. On balance sheet safety, Sera Prognostics, Inc. (SERA) carries a lower debt/equity ratio of 3% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — SERA or INVA or NTRA or PRGO?
By revenue growth (latest reported year), Natera, Inc.
(NTRA) is pulling ahead at 35. 9% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SERA or INVA or NTRA or PRGO?
Innoviva, Inc.
(INVA) is the more profitable company, earning 63. 8% net margin versus -394. 2% for Sera Prognostics, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -450. 7% for SERA. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SERA or INVA or NTRA or PRGO more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
6x forward P/E versus 11. 9x for Innoviva, Inc. — 6. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SERA: 160. 4% to $5. 00.
08Which pays a better dividend — SERA or INVA or NTRA or PRGO?
In this comparison, PRGO (9.
8% yield) pays a dividend. SERA, INVA, NTRA do not pay a meaningful dividend and should not be held primarily for income.
09Is SERA or INVA or NTRA or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Innoviva, Inc.
(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Sera Prognostics, Inc. (SERA) carries a higher beta of 1. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, SERA: -83. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SERA and INVA and NTRA and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SERA is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; NTRA is a mid-cap high-growth stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while SERA, INVA, NTRA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.